[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545731":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":40,"responsibleParty":66,"collaborators":10,"id":68,"slug":10,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":81,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Prophylactic chemoradiotherapy",null,"pT1a -MM and pT1b-SM1 without pathological risk factors",[13],"Radiation: chemo-radiation",{"label":15,"type":10,"description":16,"interventionNames":17},"Intensive chemoradiotherapy","pT1b-SM2; pT1a -MM and pT1b-SM1 with pathological risk factors",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Radical chemoradiotherapy","Positive vertical margin or unknown margin",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"RADIATION","chemo-radiation","different Chemo-radiotherapy regimen",[15,9,19],[29],{"name":30,"affiliation":5,"role":31},"Jing Xu, MD","STUDY_CHAIR",[33,37],{"name":30,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","0086-0571-87783521","jing_xu@zju.edu.cn",{"name":38,"role":34,"phone":35,"phoneExt":10,"email":39},"Qichun Wei, PHD","qichun_wei@zju.edu.cn",[41,57],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The Second Affiliated Hospital of Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310000","China","CN",{"type":50,"coordinates":51},"Point",[52,53],120.16142,30.29365,{"lat":53,"lon":52},[56],{"name":30,"role":34,"phone":35,"phoneExt":10,"email":36},{"facility":58,"status":59,"city":44,"state":10,"zip":10,"country":47,"countryCode":48,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"The Second Affiliated Hospital of Zhejiang University, School of Medicine","NOT_YET_RECRUITING",{"type":50,"coordinates":61},[52,53],{"lat":53,"lon":52},[64],{"name":65,"role":34,"phone":35,"phoneExt":10,"email":36},"Jing Xu",{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100545731",false,"NCT06385717","Multicenter Cohort Study of ESD and Chemo-radiotherapy for High-risk Early-stage Esophageal Cancer","Multicenter Cohort Study of Chemo-radiotherapy After Endoscopic Submucosal Dissection for High-risk Early-stage Esophageal Cancer","ESCORT","Inclusion Criteria:\n\n* 1\\. Esophageal cancer patients who are pathologically confirmed as pT1a-MM stage or pT1b stage after endoscopic submucosal dissection； 2. No definite contraindications for chemo-radiotherapy； 3. Informed consent has been signed； 4. Refused surgery after endoscopic submucosal dissection.\n\nExclusion Criteria:\n\n* 1\\. Severe heart, brain, lung disease or renal dysfunction; 2. Previous history of other malignancies; 3. Prior radiation or chemotherapy 4. Researchers consider it inappropriate to participate in this experiment","ALL","18 Years","75 Years",{"count":79,"type":80},120,"ESTIMATED","3 Years","OBSERVATIONAL","This multicenter, prospective observational cohort study has the potential to optimize individualized chemoradiotherapy regimen for early-stage esophageal cancer patients who have received endoscopic submucosal dissection.",[85],"Esophagus Cancer",[87],"esophagus cancer; radio-chemotherapy; ESD","2024-04-25",{"date":90,"type":91},"2024-04-26","ACTUAL",{"date":93,"type":80},"2024-05-01",{"date":95,"type":80},"2029-01-31",{"name":5,"class":6},2]